Market Movers (8-K)
See all →Jade Biosciences announced positive interim Phase 1 data for JADE101, a potential best-in-class therapy for IgA nephropathy, and provided a corporate update highlighting a strong cash runway into late 2028.
Capital raise
Jade Biosciences has entered into a material definitive agreement, securing an exclusive license for antibody technology from Paragon Therapeutics, Inc., with potential milestone payments and royalties.
Jade Biosciences has appointed industry veteran Dr. Mark Eisner to its Board of Directors to bolster clinical development expertise.
Jade Biosciences, Inc. announced the approval of amended Articles of Incorporation and Bylaws, including a jury trial waiver and updated voting standards, following its 2026 Annual Meeting.
Jade Biosciences has priced a public offering of 10,000,000 shares of common stock at $15.00 per share to raise approximately $140.3 million in net proceeds.
Capital raise
Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, an investigational antibody for IgA nephropathy, showing significant and sustained IgA reductions with a favorable safety profile.
Quarterly Earnings (10-Q)
See all →Jade Biosciences, Inc. disclosed its second-quarter 2026 financial results, highlighting increased research and development spending and general administrative costs, alongside positive interim clinical data for its lead candidates.
Worse than expected
Capital raise
Jade Biosciences, Inc. reported increased operating expenses, particularly in research and development, for the first quarter of 2026, while maintaining a substantial cash and investment balance.
Worse than expected
Capital raise
Jade Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $25.2 million for Q3 2025, while significantly enhancing its liquidity with a $135 million private placement completed in October 2025.
Capital raise
Jade Biosciences, Inc. reports a strong cash position of $220.9 million following a reverse recapitalization and pre-closing financing, enabling advancement of its autoimmune disease pipeline.
Better than expected
Capital raise
Aerovate Therapeutics reports Q1 2025 results, discontinues AV-101 program, and focuses on a merger with Jade Biosciences.
Worse than expected
10-Q: Aerovate Therapeutics Announces Merger with Jade Biosciences Following Disappointing Trial Results
Aerovate Therapeutics will merge with Jade Biosciences after halting its Phase 3 trial for AV-101 due to negative results, and plans a significant cash dividend to pre-merger stockholders.
Worse than expected
Capital raise
Annual Reports (10-K)
Jade Biosciences, a clinical-stage biopharmaceutical company, reported significant pipeline progress for its autoimmune disease therapies and a strong cash position following recent capital raises, despite ongoing net losses.
Worse than expected
Capital raise
Aerovate Therapeutics discontinues AV-101 development for PAH following Phase 2b results and enters a merger agreement with Jade Biosciences to maximize shareholder value.
Capital raise
Worse than expected
Aerovate Therapeutics, a clinical-stage biopharmaceutical company, has released its full year 2023 results, highlighting progress in its Phase 2b/Phase 3 clinical trial for AV-101, a treatment for pulmonary arterial hypertension.
Capital raise
Insider Trading (Form 4)
See all →Mark Eisner, a Director at Jade Biosciences, Inc., acquired stock options for 47,675 shares of common stock.
Director Christopher W. Cain was granted 34,843 stock options in Jade Biosciences, Inc. as part of his service arrangement.
Director Eric Dobmeier was granted 34,843 stock options in Jade Biosciences, Inc. as part of a standard equity compensation arrangement.
Director Lawrence Otto Klein was granted 34,843 stock options in Jade Biosciences, Inc. as part of his compensation.
Director Erin Lavelle was granted 34,843 stock options in Jade Biosciences, Inc. as part of a standard equity compensation arrangement.
Fairmount Funds Management and associated directors were granted 34,843 stock options in Jade Biosciences, Inc.
Proxy Statements (Def-14A)
Jade Biosciences, Inc. has issued its proxy statement, inviting stockholders to its 2026 Annual Meeting of Stockholders on June 9, 2026, to vote on director elections, auditor ratification, and a charter amendment.
Aerovate Therapeutics will hold its annual stockholders meeting on June 5, 2024, to vote on the election of directors and the ratification of KPMG LLP as the company's independent accounting firm.
Aerovate Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 5, 2024, to elect directors and ratify the appointment of KPMG LLP as the independent accounting firm.
New Public Companies (S-1)
Jade Biosciences filed a Form S-1 to register 3.21 million shares for resale from its December 2025 $45 million PIPE, with no proceeds to the company.
Capital raise
Jade Biosciences, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 16.1 million common shares by selling stockholders, following a $135 million private placement and a reverse merger.
Capital raise
Schedule 13D - Activist Investments
See all →Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Jade Biosciences following a lock-up agreement.
Capital raise
Sofinnova Venture Partners X and its affiliates now hold less than 5% of Jade Biosciences' common stock following a merger and reverse stock split.
Fairmount Funds Management and its affiliates increased their beneficial ownership in Jade Biosciences, Inc. to 19.99% through a recent $20 million private placement.
Capital raise
SCHEDULE 13D: Fairmount Funds Management Discloses Significant 19.99% Stake in Newly Merged Jade Biosciences, Inc.
Fairmount Funds Management LLC and its affiliates have disclosed a 19.99% beneficial ownership stake in Jade Biosciences, Inc. following a recent merger and corporate restructuring.
Capital raise
SCHEDULE 13D/A: RA Capital Management Reduces Stake in Jade Biosciences Following Merger and Reverse Stock Split
RA Capital Management and its affiliates have reduced their beneficial ownership in Jade Biosciences, Inc. to below 5% following a corporate merger and reverse stock split.
Capital raise
SCHEDULE 13D/A: Atlas Venture Reports Diluted Stake in Jade Biosciences Following Aerovate Merger and Reverse Stock Split
Atlas Venture entities have reported a significant reduction in their beneficial ownership of Jade Biosciences, Inc. common stock, falling below the 5% threshold, following the completion of Jade Biosciences' merger with Aerovate and a subsequent 1-for-35 reverse stock split.
Schedule 13G - Passive Investments
See all →A group of investment entities, including Venrock Healthcare Capital Partners, has reported a combined beneficial ownership of 8.3% in Jade Biosciences, Inc. as of June 30, 2026.
Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported beneficial ownership of 5.0% of Jade Biosciences, Inc. common stock.
Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of over 5% of Jade Biosciences, Inc. common stock.
Janus Henderson Group Ltd. has reported beneficial ownership of 10.6% of Jade Biosciences, Inc. common stock, totaling 6,273,262 shares, as of June 30, 2026.
Janus Henderson Group plc has reported beneficial ownership of 3,105,669 shares, representing 6.3% of the outstanding common stock of Jade Biosciences, Inc.
Janus Henderson Group plc has reported a 6.2% beneficial ownership stake in JADE BIOSCIENCES, INC., holding over 3 million shares as of December 31, 2025.